Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PN-235 · 1 trial · 1 indication
Number and severity of Adverse Events
| Arm | Type | Description |
|---|---|---|
| Single Dose | EXPERIMENTAL | Single dose administration |
| Multiple Dose | EXPERIMENTAL | Multiple dose administration |
| Solid Dose Comparison | EXPERIMENTAL | Solid dose administartion |
| Name | Type | Description |
|---|---|---|
| PN-235 | DRUG | Active Drug |
| Placebo | DRUG | Matching Placebo |
Key Inclusion Criteria: * Subjects must have BMI between 18 and 32 * Subjects must be non-smokers or social smokers * Subjects must comply with contraception requirements * Subjects must be willing to consume meals provided by the clinical center Key Exclusion Criteria: * Subject must not have hi...
PN-235 is an investigational small molecule being developed by Protagonist Therapeutics, Inc. (PTGX). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and its therapeutic area is classified as Other.
PN-235 is being studied for use in healthy volunteers. It is currently in Phase 1 clinical development, and its intended therapeutic indication has not been specified beyond healthy volunteer studies. The drug is an investigational small molecule.
PN-235 is being developed by Protagonist Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker PTGX. The company is conducting clinical trials to evaluate the drug in healthy volunteers.
PN-235 is in Phase 1 clinical development. It has completed one Phase 1 trial in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
PN-235 has been studied in one completed Phase 1 clinical trial, NCT04621630, titled "Pharmacokinetics of PN-235 in Healthy Volunteers." The trial enrolled 107 participants in Australia and was a randomized, double-blind, controlled study.
PN-235 is a distinct investigational drug developed by Protagonist Therapeutics. No alternative names for PN-235 have been reported in clinical trial registries.